Kiadis Pharma

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Withdrawn	Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19 Covid19	Phase 1 / Phase 2	2020-12-01
Withdrawn	Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)	Phase 2	2020-11-13
Terminated	Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentica Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome	Phase 3	2017-11-29
Completed	Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Al Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome	Phase 2	2015-10-09
Completed	Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilic Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome	—	2014-09-01
Completed	Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients Wi Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome	Phase 2	2013-03-01
Terminated	Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma	Phase 2 / Phase 3	2009-08-01
Completed	Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease ( Graft vs Host Disease	Phase 1 / Phase 2	2005-11-01
Completed	NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Tumors	Phase 1 / Phase 2	2005-09-01
Completed	Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patien Hematologic Diseases, Hematologic Malignancies	Phase 1 / Phase 2	2005-01-01